Skip to content

A Clinical Study of Talc Alone Versus Talc Plus Betadine for Lung Fluid Control in Cancer�

A randomized controlled trial comparing the efficacy and safety of Dual agent pleurodesis (BETADINE + TALC) vs Single agent pleurodesis (TALC) in malignant pleural effusions. - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108953
Enrollment
60
Registered
2026-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J910- Malignant pleural effusion

Interventions

Intervention1: talc + povidone-iodine: combining these two effective agents with inflammatory and sclerosing properties may be expected to enhance pleural symphysis, reduce recurrence of effusion, and

Sponsors

Dr Venkata Nagarjuna Maturu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age greater than 18 years at the time of enrollment. 2.Diagnosed of malignant pleural effusion (MPE) by cytology or histology from pleural fluid or tissue. 3.Symptomatic effusion requiring intervention. 4.Expandable lung, demonstrated by chest radiograph or ultrasound after initial thoracentesis or fluid drainage. 5.Eastern Cooperative Oncology Group (ECOG) performance status of 0â??2. 6.Life expectancy greater than 3 months, as judged by the treating oncologist or pulmonologist. 7.Ability to provide written informed consent and comply with study procedures and follow-up.

Exclusion criteria

Exclusion criteria: 1.Known hypersensitivity to talc or povidone-iodine (betadine). 2.Trapped lung confirmed radiographically or via thoracic ultrasound. 3.Presence of active pleural infection (empyema). 4.Recent pleurodesis in past 7 days. 5.Severe coagulopathy not correctable. 6.Uncontrolled systemic infection or sepsis at the time of enrollment. 7.Pregnant or breastfeeding women. 8.Participation in another interventional trial involving pleural interventions that may interfere with outcomes.

Design outcomes

Primary

MeasureTime frame
Pleurodesis success Timepoint: Day 30 post-procedure

Secondary

MeasureTime frame
Extended pleurodesis success Dyspnea improvement Procedure-related adverse events Hospital stay durationTimepoint: 1.Extended pleurodesis success-Day 90 2.Dyspnea improvement-Day 3â??7, Day 30, and Day 90 3.Procedure-related adverse events-Within 3-7 days post-procedure 4.Hospital stay duration-Index hospitalization

Countries

India

Contacts

Public ContactDr Venkata Nagarjuna Maturu

Yashoda Hospitals

arjunjipmer@yahoo.co.in9000060507

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026